인플루엔자 백신 시장 규모, 점유율 및 성장 분석 : 백신 유형별, 백신 제제별, 기술별, 투여 경로별, 연령층별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Influenza Vaccine Market size was valued at USD 7.91 Billion in 2024 and is poised to grow from USD 8.46 Billion in 2025 to USD 14.52 Billion by 2033, growing at a CAGR of 6.98% during the forecast period (2026-2033).

The influenza virus continues to circulate globally, leading to persistent regional epidemics and outbreaks with significant mortality rates. An annual adaptation of the vaccine strain is necessary to align with the evolving nature of the virus. As the frequency of influenza outbreaks rises, there is a notable increase in the demand for influenza vaccines, which are recommended by reputable health organizations globally. Governments are actively promoting vaccination campaigns to maximize protection during flu seasons. Concurrently, pharmaceutical companies face ongoing challenges in developing effective vaccines tailored to specific strains. This combination of rising epidemic prevalence and the continuous need for innovative vaccine solutions positions the Influenza Vaccine Market for substantial growth driven by heightened consumer demand for effective influenza vaccination.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Influenza Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Influenza Vaccine Market Segments Analysis

Global Influenza Vaccine Market is segmented by Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Quadrivalent and Trivalent. Based on Vaccine Formulation, the market is segmented into Inactivated and Live Attenuated. Based on Technology, the market is segmented into Egg-based Production, Cell-based Production and Recombinant-based Production. Based on Route of Administration, the market is segmented into Injection and Nasal Spray. Based on Age Group, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital & Pharmacies, Government & Institutional Supply and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Influenza Vaccine Market

The global market for influenza vaccines is significantly driven by the rising support and surveillance efforts from governments aimed at enhancing vaccination initiatives. Effective monitoring at both national and international levels is essential for overseeing the supply chain, distribution, and administration of influenza vaccines. Organizations such as the World Health Organization, in partnership with various governments, actively track vaccine demand and implement immunization programs worldwide to optimize vaccine availability in diverse regions. This concerted effort helps ensure that adequate vaccine supplies are maintained, thereby addressing public health needs and promoting widespread vaccination against influenza.

Restraints in the Global Influenza Vaccine Market

The global influenza vaccine market faces significant restraints primarily due to the prolonged and intricate nature of vaccine development, which necessitates meticulous evaluation of safety, quality, and efficacy. This process is often hindered by the complexities associated with global clinical studies and the varying regulatory frameworks imposed by different countries. These discrepancies can lead to substantial delays in the introduction of new vaccines, as regulatory bodies frequently require extensive data from multiple regions. Additionally, differing labeling standards and compressed timelines further complicate the execution of clinical trials on a global scale. As a result, these stringent requirements and the extended duration for trial conduct may impede progress in product development.

Market Trends of the Global Influenza Vaccine Market

The Global Influenza Vaccine market is witnessing a positive trend, driven by heightened awareness of public health measures in the wake of the coronavirus pandemic. This surge in flu vaccination rates is largely attributed to intensified advocacy from health experts and government initiatives promoting free vaccination programs across diverse regions. Consequently, both developed and developing nations have observed an uptick in participation in flu immunization campaigns. Furthermore, the growing recognition of the value of preventive healthcare continues to propel investments in vaccine research and development, ultimately fostering a more robust and responsive influenza vaccine market landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies
• Startup Analysis
• Patent Analysis

Global Influenza Vaccine Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Quadrivalent
• Trivalent

Global Influenza Vaccine Market Size by Vaccine Formulation & CAGR (2026-2033)

• Market Overview
• Inactivated
• Live Attenuated

Global Influenza Vaccine Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Egg-based Production
• Cell-based Production
• Recombinant-based Production

Global Influenza Vaccine Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Injection
• Nasal Spray

Global Influenza Vaccine Market Size by Age Group & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Influenza Vaccine Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital & Pharmacies
• Government & Institutional Supply
• Other

Global Influenza Vaccine Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
  • US
  • Canada
• Europe (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Sanofi Pasteur (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK, UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seqirus (CSL, Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinovac Biotech (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Farma (Indonesia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Biologicals B.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adimmune Corporation (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIKEN Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Changchun BCHT Biotechnology (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Scinai Immunotherapeutics Ltd (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altimmune, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Osivax (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations